The strengths of the present systematic review include the following (1) the both clinical trials and observational studies were inserted in the analysis; (2) serum chemerin levels were compared in the PCOS and control groups with regard and regardless of BMI or sample size; further, (3) serum chemerin levels were compared in PCOS groups with different BMI. Here, RARRES2 is linked to polycystic ovary syndrome.